NCT04982055

Intravenous Versus Subcutaneous Administration of Low Molecular Weight Heparin for Thromboprophylaxis in Critically Ill Patients

Intravenous Versus Subcutaneous Administration of Low Molecular Weight Heparin for Thromboprophylaxis in Critically Ill Patients: a Randomized Controlled Trial

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Clinique Saint Pierre Ottignies · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Objective: To compare the pharmacokinetic profiles of intravenous versus subcutaneous route of administration of LMWH for thromboprophylaxis in critically ill patients

Detailed description

The study is a prospective, monocentric, randomized trial. Patients are randomized to the IV route of administration over a 4-hours infusion of nadroparin 3800 IU or to the SC route of administration. Randomization is stratified according to the need for vasopressor or not. Anti-Xa activity is measured at baseline, and at 1, 2, 4, 6, 8, 12 and 24 hours after the administration was started.

Conditions

• Critical Illness

Interventions

Type	Name	Description
DRUG	Nadroparin (intravenous Infusion)	Intravenous route of administration over a 4-hours infusion of nadroparin 3800 IU
DRUG	Nadroparin (subcutaneous group)	Subcutaneous route of administration of nadroparin 3800 IU

Timeline

• Start date: 2015-04-08
• Primary completion: 2020-12-31
• Completion: 2020-12-31
• First posted: 2021-07-29
• Last updated: 2021-07-29